Cott (TSE:PRM – Get Free Report) was upgraded by equities researchers at BMO Capital Markets to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
A number of other equities research analysts have also issued reports on PRM. William Blair raised shares of Cott to a “strong-buy” rating in a report on Thursday, October 24th. Raymond James cut shares of Cott from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 2nd.
Check Out Our Latest Analysis on PRM
Cott Trading Up 0.7 %
About Cott
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
Further Reading
- Five stocks we like better than Cott
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Insider Trading – What You Need to Know
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What Are the FAANG Stocks and Are They Good Investments?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Cott Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cott and related companies with MarketBeat.com's FREE daily email newsletter.
